Adjuvant Treatment for Small-Size, Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Escalation or De-Escalation?

Affiliation

• ¹ Maho Tanaka, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.